PURPOSE: mutations are among the most common recurrent alterations in non-small cell lung cancer (NSCLC), but the relationship to other genomic abnormalities and clinical impact has not been established. EXPERIMENTAL DESIGN: alterations treated at Memorial Sloan Kettering. CONCLUSIONS: -mutant lung cancers may be more sensitive to immunotherapy.
No takes yet. Share an insight, caveat, or question.
Schoenfeld et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: